泰恩康(301263.SZ)：CKBA乳膏玫瑰痤疮适应症开展II/III期无缝适应性临床试验
T&KT&K(SZ:301263) 智通财经网·2025-09-25 09:22

Core Viewpoint - The company TianKang (301263.SZ) announced that its subsidiary Jiangsu BoChuangYuan Biopharmaceutical Technology Co., Ltd. has received the Clinical Trial Approval Notice from the National Medical Products Administration, allowing the initiation of a seamless Phase II/III clinical trial for CKBA cream for the treatment of rosacea [1] Group 1 - The approval is significant as it marks a step forward in the clinical development of CKBA cream [1] - The clinical trial will focus on the indication of rosacea, which is a common skin condition [1] - This development may enhance the company's product pipeline and potential market offerings in the biopharmaceutical sector [1]